Gold­man Sachs jumps aboard Bain-backed 503(b) com­pound­ing phar­ma­cy with a $275M debt loan to sup­ply hos­pi­tals

Long the bane of the FDA’s ex­is­tence, com­pound­ing phar­ma­cies have seen a mi­nor resur­gence in the past year as short-term sav­iors for hos­pi­tal drug short­ages. Now, a 503(b) com­pa­ny spe­cial­iz­ing in hos­pi­tal meds has earned a big backer to keep ex­pand­ing its 200-drug strong port­fo­lio.

Gold­man Sachs and Owl Rock Cap­i­tal Part­ners have doled out a $275 mil­lion debt loan to Qu­Va Phar­ma, a 503(b)-cer­ti­fied out­sourc­ing fa­cil­i­ty pro­vid­ing com­pound­ed drugs to hos­pi­tals, the com­pa­ny said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.